Levi & Korsinsky, LLP announces that a class action lawsuit has been commenced in the United States District Court for the District of Arizona on behalf of shareholders who purchased Accelerate Diagnostics, Inc. (NASDAQ: AXDX) shares between March 7, 2014 and February 17, 2015.
The complaint alleges that the Company misrepresented and/or failed to disclose that its main product, the ID/AST system—formerly known as the BACcel system—requires a positive blood culture to diagnose pathogens in a blood sample. On February 18, 2015, Seeking Alpha published an article asserting that though Accelerate Diagnostics had claimed it had developed a technique for diagnosing pathogens in a blood sample without the need of a blood culture, this test did in fact require a blood culture, significantly reducing its value. Upon this news shares of Accelerate Diagnostics fell more than 18% on February 20, 2015. If you suffered a loss in Accelerate Diagnostics you have until May 18, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.